CJC-1295 + Ipamorelin 10mg Blend
Dual-pathway growth hormone secretagogue blend pairing a synthetic GHRH analog with a selective ghrelin receptor agonist.
Mechanism
CJC-1295 activates pituitary GHRH receptors while ipamorelin selectively stimulates GHSR-1a ghrelin receptors, generating synergistic pulsatile growth hormone secretion.
Dosing
Preclinical models evaluate 300–500 mcg once daily administered subcutaneously on a 5 days on / 2 days off schedule.
Reconstitution
Add 3.0 mL bacteriostatic water to achieve a working concentration of 3.33 mg/mL total blend.
Storage
Lyophilized vials remain stable at −20 °C; reconstituted solutions must be stored refrigerated between 2 °C and 8 °C.
Mix & measure CJC-1295 + Ipamorelin 10mg Blend
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure CJC-1295 + Ipamorelin 10mg Blend
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 33.3
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Initial Evaluation (Days 1–5) | 300 mcg once daily (5 days on / 2 days off) | 9 units (0.09 mL) |
| Titration Phase (Weeks 2–4) | 400 mcg once daily (5 days on / 2 days off) | 12 units (0.12 mL) |
| Maintained Research (Weeks 5+) | 500 mcg once daily (5 days on / 2 days off) | 15 units (0.15 mL) |
Reconstitution Steps
- 1
Remove the 10mg lyophilized peptide vial from the freezer and allow it to equilibrate to room temperature for 15–20 minutes.
- 2
Disinfect the rubber stoppers of both the peptide vial and the bacteriostatic water vial using sterile alcohol swabs.
- 3
Using a sterile syringe, draw exactly 3.0 mL of bacteriostatic water.
- 4
Insert the needle at an angle into the peptide vial and allow the liquid to flow slowly down the inner glass wall to prevent shearing.
- 5
Gently roll and swirl the vial between hands until the powder fully dissolves; avoid vigorous shaking.
- 6
Label the vial with reconstitution date and concentration (3.33 mg/mL), and immediately refrigerate at 2–8 °C.
Supplies Needed
Peptide Vial
Contains 10 mg lyophilized CJC-1295 and Ipamorelin blend; one vial provides approximately twenty to thirty-three doses depending on the daily target.
Insulin Syringes (U-100)
Calibrated 0.3 mL or 0.5 mL U-100 syringes for precise micro-volume administration; approximately 20 to 25 syringes needed per month of study.
Bacteriostatic Water
Sterile multi-dose diluent containing 0.9% benzyl alcohol; 3.0 mL is required per 10 mg vial for reconstitution.
Alcohol Swabs
Used to sanitize vial stoppers and work surfaces before reconstitution and withdrawal; approximately 40 to 60 swabs required per protocol cycle.
Why researchers study it
Sustained pulsatile GH release
Downstream IGF-1 elevation
Body composition and nitrogen balance
Receptor crosstalk and somatotroph dynamics
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
The CJC-1295 and Ipamorelin 10mg blend combines two complementary secretagogues formulated in an equal ratio to investigate amplified growth hormone dynamics. CJC-1295 functions as a synthetic growth hormone-releasing hormone analog that binds pituitary somatotroph receptors, stimulating adenylate cyclase to prolong endogenous growth hormone transcription and basal tone. In contrast, ipamorelin functions as a selective growth hormone secretagogue receptor agonist that triggers rapid intracellular calcium influx, evoking sharp, pulsatile secretory bursts without significantly altering baseline cortisol or prolactin concentrations. Co-administering both peptides engages distinct intracellular cascades simultaneously, producing a synergistic elevation of circulating growth hormone and downstream insulin-like growth factor 1 that exceeds the response elicited by either agent individually. Preclinical literature focuses extensively on this combination to examine natural neuroendocrine rhythmicity, preservation of negative feedback architecture, and downstream metabolic endpoints such as nitrogen retention, fat mobilization, and skeletal muscle recovery.
References
- 1.Teichman et al., The Journal of Clinical Endocrinology & Metabolism, 2006 — Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults
- 2.Raun et al., European Journal of Endocrinology, 1998 — Ipamorelin, the first selective growth hormone secretagogue
- 3.Alba et al., American Journal of Physiology-Endocrinology and Metabolism, 2006 — Long-acting GHRH analog CJC-1295 maintains pulsatile GH secretion and preserves pituitary gene expression
- 4.Gobburu et al., Journal of Pharmacology and Experimental Therapeutics, 1999 — Pharmacokinetic-pharmacodynamic modeling of ipamorelin-induced growth hormone release in animal models
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allHGH Fragment 176-191 5mg
A truncated C-terminal human growth hormone peptide investigated in laboratory settings for lipolytic signaling without glycemic perturbation.
View ProtocolCJC-1295 + GHRP-2 10mg
Dual-action GH secretagogue blend pairing a sustained GHRH analog with a pulsatile ghrelin receptor agonist for experimental GH research.
View ProtocolGHK (Copper-Free) 50mg
Uncomplexed human tripeptide Gly-His-Lys researched for extracellular matrix remodeling and copper chelation dynamics.
View Protocol